Shimano, K., Grimes, A., Rose, M., Kaicker, S., Shah, S., Briones, M., … Grace, R. (2025). End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children. In Blood (Vol. 146, pp. 738–738). American Society of Hematology. https://doi.org/10.1182/blood-2025-738

Shimano, Kristin, Amanda Grimes, Melissa Rose, Shipra Kaicker, Sanjay Shah, Michael Briones, Elizabeth Gunn, et al. “End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children.” In Blood, 146:738–738. American Society of Hematology, 2025. https://doi.org/10.1182/blood-2025-738.

Shimano K, Grimes A, Rose M, Kaicker S, Shah S, Briones M, et al. End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children. In: Blood. American Society of Hematology; 2025. p. 738–738.

Shimano, Kristin, et al. “End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children.” Blood, vol. 146, no. Supplement 1, American Society of Hematology, 2025, pp. 738–738. Crossref, doi:10.1182/blood-2025-738.

Shimano K, Grimes A, Rose M, Kaicker S, Shah S, Briones M, Gunn E, Nakano T, Lebensburger J, Lambert M, Fritch Lilla S, Jesudas R, Lee-Miller C, Thompson A, Bhat R, Rifkin-Zenenberg S, Majumdar S, Kochhar M, Crary S, Hege K, Rothman J, Ford J, Bies J, Wynn T, Hsieh L, Ruiz M, Dinu B, Wong J, Kao P-C, Arnold S, Bennett C, Despotovic J, Klaassen R, Neufeld E, Neunert C, London W, Grace R. End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children. Blood. American Society of Hematology; 2025. p. 738–738.